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Implications of serial
measurements of natriuretic
peptides in heart failure:
insights from BIOSTAT-CHF
Natriuretic peptides [NP, including B-type
natriuretic peptide (BNP) and amino-terminal
prohormone of BNP (NT-proBNP)] are
the gold-standard biomarkers in heart fail-
ure (HF) management,1 with NP levels at
presentation/admission routinely used for
diagnostic and prognostic purposes.2 NP
levels at discharge/follow-up also show
association with outcomes,3 and NP levels
following HF treatment add further value to
tailoring risk.4 However, the usefulness of NP
serial measurements beyond conventional
HF treatment in clinical practice still remains
a matter of controversy.3,5 A cohort with
current HF guideline-based treatment would
provide an ideal setting to revisit usefulness
of NP serial measurements in risk stratifi-
cation of HF patients, including the role of
recently identified BNP molecular forms.6
The European multi-national BIOlogy Study
to TAilored Treatment in Chronic Heart
Failure (BIOSTAT-CHF) provides an oppor-
tunity for the aforementioned analysis, being
a European cohort in which serial sampling of
NPs was done before and after titration of HF
medications according to current European
guidelines in a multi-centre, observational,
real-world setting.7
The aims of the present study were to
investigate the association with HF outcomes,
effects of HF guideline treatment, and the
implications of NP serial measurement in the
BIOSTAT-CHF cohort.7
From the total cohort, 757 patients with
available plasma samples at baseline (V1) and
at follow-up (V2, approximately 9 months
apart) were measured for BNP and BNP
molecular form, BNP 5–326 (see Table 1 for
methods on measurements). NT-proBNP
measurement was only available at baseline
(V1); therefore, analyses related to this
peptide were limited to baseline (V1). The
primary endpoints were all-cause mortal-
ity and a composite of mortality with HF
rehospitalisation (mortality/HF) at 3 years,
and overall from baseline (V1). Changes in
dosage titrations and response of peptide
levels were investigated by splitting the pop-
ulation into two groups based on treatment
up-titration, as previously reported (see
online supplementary material).7
Demographics and clinical measurements
are described in Table 1. At baseline (V1),
NP levels (BNP, NT-proBNP, and BNP 5–32)
were strongly correlated with each other
(rs = 0.635–0.904, P< 0.001). Cox regres-
sion modelling showed baseline BNP levels
to be associated with mortality [hazard
ratio (HR) 1.99, 95% confidence interval
(CI) 1.23–3.23; P = 0.005] and mortality/HF
(HR 1.72, 95% CI 1.25–2.37; P = 0.001).
NT-proBNP and detection of BNP 5–32
were similarly associated with mortality (HR
≥1.85, 95% CI 1.15–3.20; P≤ 0.012) and
mortality/HF [HR ≥1.54, 95% CI 1.14–3.22;
P≤ 0.015) after adjustment for the BIOSTAT-
CHF compact model7 (Table 2). All three NPs
retained their associations with outcomes
after further adjustment with additional
NP confounders (online supplementary
Table S1A). With regard to the effect of HF
treatment, significantly reduced BNP levels
were observed only when at least one med-
ication was up-titrated, whereas BNP 5–32
was reduced regardless of drug up-titration
(Table 3). A general linear model analysis for
repeated measures confirmed these find-
ings (online supplementary Table S1B). For
serial measurements (Table 4), when BNP
baseline (V1) and follow-up (V2) levels were
compared, follow-up (V2) measurements
were more strongly associated with all cause-
mortality than baseline (V1) (chi-square:
67.1 vs. 16.0). However, even if the combi-
nation of baseline (V1) and follow-up (V2)
measurements were significant (chi-square:
66.7, P< 0.001), there was no added value
to the follow-up (V2) measurement alone, as
the role of the baseline (V1) measurement
was not preponderant (P = 0.878). Similarly,
follow-up BNP 5–32 measurement showed a
stronger association with all-cause mortality
than the baseline value (chi-square: 64.3 vs.
18.8); however, the combination of baseline
(V1) and follow-up (V2) measurements was
significantly better (chi-square: 69.8), with the
baseline (V1) level providing additional value
(chi-square: 5.5, P = 0.017) to follow-up (V2)
measurement alone. Furthermore, in patients
that did not achieve ≥50% dose treatment
but still showed BNP 5–32 to decrease
from detectable to undetectable levels (or
high-low for BNP) exhibited better outcomes
than those who displayed increased levels at
follow-up (online supplementary Figures S1
and S2).
There are three main findings of the
present investigation. Firstly, baseline NP
levels were independently associated with
adverse outcomes, with comparable results
for BNP, NT-proBNP, and BNP 5–32. Sec-
ondly, response to HF guideline treatment
up-titration was associated with a decrease
in both BNP and BNP 5–32 levels. Finally,
even if both BNP and BNP 5–32 showed
stronger association with all-cause mortal-
ity at follow-up measurement compared
to baseline, combination of baseline and
follow-up measurements did not add value
for BNP beyond follow-up alone, whereas
BNP 5–32 did.
The recent North American GUIDE-IT
trial8 showed guideline-directed medical
therapy (GDMT) guided by NT-proBNP
levels was not superior to GDMT alone and
that GDMT intensity was associated with
lower NT-proBNP levels and further that low
NP levels at follow-up (NT-proBNP levels
≤1000 pg/mL during GDMT) were associated
with better outcomes.9 Consistent with
this, the present study based on a European
real-world cohort showed that follow-up
values after guideline-based treatment were
more associated with outcomes for both
BNP and BNP 5–32 (online supplementary
Figures S3 and S4). In this context, analysis
of the NP response in the BIOSTAT-CHF
cohort, with medications optimised according
to HF guidelines, confirmed the association
of baseline NP levels (BNP, NT-proBNP and
BNP 5–32) with adverse outcomes, and
follow-up levels after treatment to show
better association with adverse outcomes
when compared to baseline levels, consistent
with previous reports.1,2,4,10,11 This is in line
with a previous finding in another real-world
cohort conducted in the UK in which the
measurement of follow-up NT-proBNP, after
optimisation of pharmacotherapy, although
preceding current guidelines, provided more
value than baseline measurements alone.10
The difference in added value of combined
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Patient characteristics
Patients with follow-up visit (n = 757)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Visit 1 Visit 2 P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .












LV ejection fraction (%) 30 (25–36) 35 (28–43) <0.001*
Pulmonary congestion 49% 11% <0.001*
Peripheral oedema 49% 24% <0.001*
Systolic blood pressure (mmHg) 122 (110–140) 123 (110–140) 0.654
Diastolic blood pressure (mmHg) 75 (68–85) 75 (66–80) 0.011*
Heart rate (bpm) 75 (65–88) 70 (61–80) <0.001*
Beta-blocker 85% 93% <0.001*
ACEi or ARB 74% 89% <0.001*
Haemoglobin (g/dL) 13.4 (12.1–14.5) 13.3 (12.1–14.3) 0.030*
Urea (mmol/L) 9.4 (6.8–14.3) 10 3 (7.1–15.7) <0.001*
eGFRa (mL/min/1.73 m2) 66 (49–82) 61 (46–79) <0.001*
Sodium (mmol/L) 140 (137–142) 139 (137–142) 0.209
BNP (pg/mL) 202 (85–406) 134 (49–349) 0.001*
NT-proBNP (ng/L) 2236 (971–4654) – –








ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BNP, B-type natriuretic peptide; BP, blood pressure; COPD, chronic obstructive pulmonary
disease; eGFR, estimated glomerular filtration rate (Chronic Kidney Disease Epidemiology Collaboration formula); HF, heart failure; LV, left ventricular; NT-proBNP, N-terminal
pro B-type natriuretic peptide; NYHA, New York Heart Association.
Combined data are shown as median (interquartile range) for continuous variables and as a % for categorical variables. P-values for visit 1 vs. visit 2 are quoted for Wilcoxon
matched-pair signed-rank tests for continuous variables and McNemar test for categorical variables. BNP 5–32 is reported as a ratio of molecular form signal intensity against
an internal reference standard.
BNP was measured using Luminex multiplexed bead-based immunoassays (Alere, San Diego, CA, USA) and validated in a small subset using a commercial assay [RapidPIA®,
Sekisui Medical Co.; r2 = 0.825)]. NT-proBNP measured using the Roche NT-proBNP assay (Roche Diagnostics, Risch-Rotkreuz, Switzerland). BNP 5–32 was measured
using matrix-assisted laser desorption ionisation-time of flight-mass spectrometry (MALDI-ToF-MS).6 BNP 4–32 and BNP 3–32 were also detected in the same assay as BNP
5–32 but were not as sensitive and not comparable to BNP and NT-proBNP, and therefore omitted from analyses.
aValues recorded as % detection [median (interquartile range)].
*P< 0.05.
use of baseline and follow-up measurements
for association with mortality observed for
BNP and BNP 5–32 in the present study
may reflect different responses to treat-
ment, with BNP levels being affected by
treatment but not BNP 5–32 levels as a
result of differential peptide processing in HF
patients. BNP molecular forms may provide
a more treatment-independent outcome
biomarker. In the era of peptidase inhibitors
(i.e. sacubitril/valsartan, dipeptidyl peptidase-
4 inhibitors), monitoring NPs including
molecular forms might allow further insight
into NP processing that appear to be altered
in HF.
As limitations, BIOSTAT-CHF was a non-
randomised observational study, therefore
it is not possible to infer causality to our
findings or provide a mechanistic explanation.
This study involved only European centres,
and 99% of patients were Caucasian; there-
fore, the findings of this study may not be
representative of HF patients at a global level.
In conclusion, findings from the BIOSTAT-
CHF study, as a real-world cohort, support
the role of serial measurement of NPs in
clinical practice, with follow-up BNP and BNP
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Independent prediction abilities of baseline natriuretic peptides for overall outcomes of death and death/heart
failure
Multivariate Cox model Mortality Mortality/HF
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HR 95% CI P-value HR 95% CI P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
BNPb 1.99 1.23–3.23 0.005* 1.72 1.25–2.37 0.001*
BNP 5–32a 2.01 1.26–3.20 0.003* 1.54 1.14–2.08 0.005*
NT-proBNPb 1.85 1.15–2.99 0.012* 2.33 1.69–3.22 <0.001*
BNP; B-type natriuretic peptide; CI, confidence interval; HF, heart failure; HR, hazard ratio; NT-proBNP, N-terminal pro B-type natriuretic peptide.
The compact risk model for mortality adjusted for age, haemoglobin, blood urea and use of beta-blocker at baseline. The compact risk model for mortality/HF included age,
previous HF hospitalisation, peripheral oedema, systolic blood pressure, haemoglobin, sodium and use of beta-blocker at baseline.
a Dichotomised according to detection or no detection of the peak.
b Values were log transformed.
Table 3 Response to guideline-based treatment for B-type natriuretic peptide (BNP) and BNP 5–32
Dose up-titration BNP (pg/mL) BNP 5–32a
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
n V1 V2 P-value V1 V2 P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ACEi
<50% 325 228 [100–467] 161 [69–420] 0.359 0.3 [0.0–0.5] 0.0 [0.0–0.3] <0.001*
≥50% 432 169 [77–344] 114 [39–283] 0.001* 0.0 [0.0–0.5] 0.0 [0.0–0.0] <0.001*
Beta-blocker
<50% 424 183 [85–390] 142 [54–382] 0.389 0.2 [0.0–0.5] 0.0 [0.0–0.3] <0.001*
≥50% 333 208 [88–413] 125 [43–291] <0.001* 0.0 [0.0–0.5] 0.0 [0.0–0.0] <0.001*
Both drugs
Both <50% 684 200 [85–408] 141 [56–382] 0.362 0.2 [0.0–0.5] 0.0 [0.0–0.3] <0.001*
Both ≥50% 73 206 [86–391] 121 [37–251] <0.001* 0.0 [0.0–0.5] 0.0 [0.0–0.0] <0.001*
ACEi, angiotensin-converting enzyme inhibitor; BNP, B-type natriuretic peptide; V1, visit 1 (enrolment); V2, visit 2 (9-month follow-up) <50% less than 50% of optimal
recommended dosage, ≥50% of optimal recommended dosage.
Values are reported as median [interquartile range].
aBNP 5–32 values reported as a ratio of the mass spectral peak signal intensity against adrenocorticotropic hormone (internal reference standard).
Table 4 Cox models of baseline B-type natriuretic peptide (BNP) 5–32, follow-up BNP 5–32, and combination of BNP
5–32 detection to illustrate whether their combination can better explain all-cause mortality





. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
BNPa (V1) only 16.0 16.0 2.04 (1.44–2.90) <0.001*
BNPa (V2) only 67.1 67.1 4.03 (2.88–5.65) <0.001*
BNPa (V2) + 66.7 75.1 4.00 (2.71–5.91) <0.001*
BNPa (V1) 0.4 1.04 (0.67–1.60) 0.878
BNP 5-32b (V1) only 18.8 18.8 2.14 (1.50–3.04) <0.001*
BNP 5-32b (V2) only 64.3 64.3 3.77 (2.66–5.34) <0.001*
BNP 5-32b (V2) + 69.8 52.2 3.28 (2.28–4.73) <0.001*
BNP 5-32b (V1) 5.5 1.61 (1.09–2.37) 0.017*
BNP, B-type natriuretic peptide; CI, confidence interval; HR, hazard ratio; V1, visit 1; V2, visit 2.
Univariate Cox regression analysis was performed initially for (i) baseline measurement, then for (ii) follow-up measurement, and finally for (iii) baseline + follow-up generating
a chi-square for the overall model and also chi-square values for the contribution of the individual variables to the overall model, hence chi-square if term removed.
aValues were log transformed.
bDichotomised according to detection or no detection of the peak.








































































































































































































































5–32 levels adding value to risk stratification
in HF patients. Future studies are needed in
cohorts with NP-modulating treatment (i.e.
peptidase inhibitors).
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